PPT-A brief overview of CKD

Harshani D Perera Senior Registrar Nephrology SJGH 09012018 CKD definition Kidney damage or eGFR lt 60 mlmin173m2 persisting for 3 months despite the cause several classifications . DATE DESCRIPTION BY CKD BY WEIGHT POUNDS VOLUME CUBIC FEET FIGURE NUMBER LOCATION FIGURE NUMBER DIMENSIONS ARE SUBJECT TO MANUFACTURERS TOLERANCE AND CHANGE WITHOUT NOTICE WE CAN ASSUME NO RESPONSIBIL 2017 . Annual Data Report. Volume 1: Chronic Kidney Disease. 2. vol 1 Figure 7.1 Sources of prescription drug coverage in Medicare enrollees, by population, 201. 5. Data source: Medicare 5% sample. Point prevalent Medicare enrollees alive on January 1, 2015. Abbreviations: CKD, chronic kidney disease; LIS, Medicare Low-income Subsidy; Part D, Medicare prescription drug coverage benefit.. Learning Objectives. Utilize appropriate screening tools, such as GFR and ACR, in order to diagnose and monitor CKD patients.. Classify CKD, based on GFR and albuminuria categories, in order to guide appropriate treatment. . Data Source: National Health and Nutrition Examination Survey (NHANES), 1988–1994, 1999-2004 & 2007–2012 participants aged 20 & older. Whisker lines indicate 95% confidence intervals. Abbreviations: CKD, chronic kidney disease. This graphic also appears as Figure 1.2. Chapter 1: CKD in the General Population 2017 Annual Data Report Volume 1: Chronic Kidney Disease 2 Table A Kidney Disease Outcomes and Quality Improvement (KDOQI) CKD Staging Guidelines CKD Stage Description KDIGO Guideline Co-Chairs:. Alfred K. Cheung, MD. Johannes F.E. Mann, MD. Guideline: . Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1–S87. KDIGO 2017 Clinical Practice Guideline Update. Speaker’s Guide. Summary of KDIGO CKD-MBD Guideline Recommendations. This Speaker’s Guide combines the new recommendation statements . (noted in green) . Hyperkalemia, Metabolic Acidosis, Malnutrition, Depression & Acute Kidney Injury. Andrew . Narva. , MD, FASN & . Amy Barton . Pai. , PharmD, MHI, FASN, FCCP, FNKF. Andrew . Narva. , MD, FASN. In CKD and HD patients dysfunction of . immu. ne . sy. stem . a. lterations. . belonge. to . . involv. ing. . i. nnate. and . a. daptive. . i. mmunity. in T and B lymphocytes (. Reduced . T regulatory cells and memory cells and increased innate cells). . Narender Goel et al.. Middletown Medical PC,. Montefiore Medical Center & Albert Einstein College of . Medicine, New York. 4th International Conference on Nephrology & Therapeutics. September . Kidney Specialists, Inc.. National Kidney Foundation of Central Ohio. Board of Advisors. Medical Advisory Board. Goals of this talk:. Teach providers how to evaluate CKD patients in their office, to start the diagnostic and treatment plan. Konstantia. Ass. Prof. of Nephrology D.U.TH.. Reduced quality of life . van Haalen et al. BMC Nephrology 2020. Worse renal survival. Lamerato et al. BMC Nephrology 2022. Increase in morbidity and mortality. Crude prevalence of chronic kidney disease (CKD) among adults with hypertension was over three times as high as that among adults without hypertension (24.6% vs 7.3%, 2017–March 2020). The prevalence of CKD among those with hypertension has remained constant from 2001 through March 2020. Age-standardized trends were consistent with the crude trends.. By. Mostafa. . Abd_Elsalam,MD. MUH,MNDU. Definitions. K/DOQI, 2002. Chronic kidney disease . Epidemiology of chronic kidney disease. . U.S. Renal Data System (2013) USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease.